|Stage of funding:||Current|
Clearside Biomedical, Inc., headquartered in Alpharetta, GA, is a clinical-stage biopharmaceutical company developing first-in-class drug therapies to treat chronic, blinding diseases of the eye. Clearside’s product candidates focus on diseases affecting the retina and the choroid, especially diseases associated with macular edema, and are injected non-surgically into the suprachoroidal space with Clearside’s proprietary microinjector.
Clearside Biomedical’s goal is to be a leading pharmaceutical company focused on the development and commercialization of therapeutics to treat chronic, blinding diseases of the eye, with a particular emphasis on diseases affecting the choroid and retina.
The key elements of company's strategy are:
NovaDigm Therapeutics, a company developing innovative immuno-therapeutics and preventative vaccines for fungal and bacterial infections, today announced the publication of data from a Phase 2a study of its NDV-3A vaccine program in the journal Clinical Infectious Diseases. The data demonstrate that a single dose of NDV-3A with alum adjuvant was safe, well-tolerated, immunogenic and efficacious, leading to reduced recurrences of vaginitis in patients with recurrent vulvovaginal candidiasis (RVVC). NDV-3A is the company’s lead development candidate to potentially treat or prevent diseases caused by fungal and bacterial pathogens, including antimicrobial-resistant strains.
24 April 2018
19 April 2018
12 April 2018